Hisamitsu Pharmaceutical Co., Inc.
JPX: 4530.T0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Tokyo Stock Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Kazuhide Nakatomi
- Employees
- 2,759
- Headquarters
- Tosu, Japan
- IPO year
- 2001
- Market cap
- ¥425.2B
- Website
- https://www.hisamitsu.co.jp
Loading 4530…
Loading profile data…Frequently asked questions about 4530
What does Hisamitsu Pharmaceutical Co., Inc. (4530.T) do?
Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals, quasi-drugs, and medical devices in Japan. The company provides external pain relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; and BUTENALOCK, a remedy for athlete's foot, as well as ALLEGRA FX, a sinus medication for allergies. It also m...
Where does 4530.T trade?
Hisamitsu Pharmaceutical Co., Inc. (4530.T) trades on the Tokyo Stock Exchange.
What sector is 4530.T in?
Hisamitsu Pharmaceutical Co., Inc. (4530.T) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Hisamitsu Pharmaceutical Co., Inc.?
Kazuhide Nakatomi is the chief executive officer of Hisamitsu Pharmaceutical Co., Inc. (4530.T).
Where is Hisamitsu Pharmaceutical Co., Inc. headquartered?
Hisamitsu Pharmaceutical Co., Inc. is headquartered in Japan.
Does 4530.T pay a dividend?
Yes — Hisamitsu Pharmaceutical Co., Inc. (4530.T) paid a trailing twelve-month dividend of JPY 120.00 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did 4530.T go public?
Hisamitsu Pharmaceutical Co., Inc. (4530.T) completed its initial public offering in 2001.